Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2025 10:00 ET | Source: The Wistar Institute

The Wistar Institute Receives Exceptional Rating in Renewal of its Cancer Center Support Grant

Philadelphia, PA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The National Cancer Institute (NCI) rated The Wistar Institute’s Ellen and Ronald Caplan Cancer Center as “exceptional” for the third time in a...
December 15, 2025 10:00 ET | Source: CancerNetwork

New research in ONCOLOGY® identifies gaps between gynecologic cancer disease burden and clinical trial availability at UCLA Jonsson Comprehensive Cancer Center

New research in ONCOLOGY finds major gaps between cancer incidence and clinical trial enrollment, highlighting urgent needs for equity and better access.
November 18, 2025 08:00 ET | Source: Medidata Solutions, Inc.

National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that Medidata Health...
September 30, 2024 08:00 ET | Source: Ichnos Glenmark Innovation

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
February 26, 2024 08:30 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...
October 12, 2023 16:05 ET | Source: Immuneering Corporation

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven...
October 04, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m....
March 01, 2023 08:00 ET | Source: PDS Biotechnology Corporation

PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

FLORHAM PARK, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
October 12, 2022 07:30 ET | Source: Theratechnologies

Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACR

MONTRÉAL, 12 oct. 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou « la Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
October 12, 2022 07:30 ET | Source: Theratechnologies

Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium

MONTREAL, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...